Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : The Big Tex House of Coin -- Ignore unavailable to you. Want to Upgrade?

To: Spark who wrote (14436)	8/24/2000 6:15:05 PM
From: Spark	Read Replies (1) \| Respond to of 19297

..looking goooooood!! LOL 3:41 PM ET Aug 24, 2000: Thursday, August 24, 2000 INCR gets stem cell boost --3:41 pm - By Michael Baron In what feels like an eerie replay of the frenzied buying in biotechnology stocks earlier this year, Incara Pharmaceuticals (INCR: news, msgs) is being bid up Thursday because of its involvment with stem cell research. After driving up StemCells (STEM: news, msgs) and Aastrom BioSciences (ASTM: news, msgs) Wednesday and again today [see 10:13 am item], investors are scooping up shares of other lesser known companies that could benefit from the repeal of a ban on federal funding of research on embryotic stem cells. Incara, which is developing a liver precursor cell therapy to treat liver failure, is soaring 1 5/16, or 48.8 percent, to 4, on volume of 521,000 shares. Average daily volume is 178,100.